Charles River Laboratories International (NYSE:CRL) Announces Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Charles River Laboratories International (NYSE:CRL) announced its quarterly earnings data on Wednesday. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16, Zacks reports. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period last year, the company posted $2.46 EPS. Charles River Laboratories International updated its FY 2025 guidance to 9.100-9.600 EPS and its FY25 guidance to $9.10-$9.60 EPS.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $165.00 on Thursday. The firm has a market cap of $8.44 billion, a PE ratio of 20.65, a PEG ratio of 5.91 and a beta of 1.37. The company’s 50 day moving average price is $174.02 and its two-hundred day moving average price is $188.99. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 12-month low of $150.79 and a 12-month high of $275.00.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Finally, The Goldman Sachs Group decreased their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $197.64.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).